drugset / Trial / NCT05373147
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
Phase 0
Unknown
21 enrolled
Shanghai Mengchao Cancer Hospital
Shanghai Cell Therapy Group Co.,Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies (αPD1-MSLN-CAR T cells) in patients with solid tumors.
Timeline
- Start
- 2020-10-30
- Primary completion
- 2023-02
- Completion
- 2023-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | αPD1-MSLN-CAR T cells | Cell therapy | 100000 cells/kg | — |
| Subject | αPD1-MSLN-CAR T cells | Cell therapy | 300000 cells/kg | — |
| Subject | αPD1-MSLN-CAR T cells | Cell therapy | 1e+06 cells/kg | — |
| Subject | αPD1-MSLN-CAR T cells | Cell therapy | 3e+06 cells/kg | — |